AstraZeneca

The article discusses the necessity of enabling JavaScript to run the app, as indicated by the noscript tag within the body of the HTML document.

Capivasertib (Truqap) + abiraterone acetate (Zytiga) + androgen deprivation therapy (ADT) significantly extended radiographic progression-free survival (rPFS) vs placebo + abiraterone + ADT in PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) patients, according to phase 3 CAPItello-281 trial data. A trend toward improved overall survival (OS) was observed, with safety data consistent with known profiles. The trial remains ongoing to assess OS and other secondary end points, with final completion anticipated in March 2027.

Mount Sinai Health System opens the Hamilton and Amabel James Center for AI and Human Health, a 12-story, 65,000-square-foot facility dedicated to enhancing healthcare through AI research and development, supported by a generous gift from Hamilton and Amabel James.

The Global Neurology Clinical Trials Market is projected to reach USD 5,549.3 million by 2024 and USD 9,231.2 million by 2033 at a CAGR of 5.8%. The market includes treatments for Alzheimer's, Parkinson's, and Huntington's diseases, driven by increased research funding, stem cell therapies, genetic advancements, and AI in trial management. The US market, valued at USD 2,244.8 million in 2024, is expected to grow to USD 3,618.9 million by 2033 at a CAGR of 5.4%. Key players include Novartis, Covance, Medpace, and Charles River Laboratories. Recent trends highlight gene therapies, AI adoption, and growing collaborations.

FDA approves BridgeBio Pharma’s Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalisation. Attruby is the first approved drug targeting near-complete stabilisation of TTR, supported by positive ATTRibute-CM trial results. BridgeBio plans global approvals, with Bayer and AstraZeneca holding exclusive licenses in Europe and Japan, respectively.

AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and ADT showed significant improvement in radiographic progression-free survival (rPFS) in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, with early trends towards overall survival (OS) improvement. Safety profile consistent with known profiles of each medicine, with notable risks of hyperglycemia, diarrhea, and cutaneous adverse reactions.

TRUQAP (capivasertib) + abiraterone + ADT significantly improves radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, per CAPItello-281 Phase III trial.

GCAR to evaluate AstraZeneca's AZD1390 in GBM AGILE trial for glioblastoma, aiming to expedite effective therapy identification. Recruitment for newly diagnosed patients starts Q2 next year. Data may support BLA and NDA submissions to the FDA.